Last reviewed · How we verify
Etodroxyzine (ETODROXIZINE)
Etodroxyzine (generic name: ETODROXIZINE) is a etodroxizine drug. It is currently in Phase 2 development.
Etodroxizine is thought to work by interacting with a specific molecular target, but its exact mechanism is currently unknown.
Etodroxizine is a small molecule drug in the etodroxizine class, but its target and mechanism of action are unknown. Its commercial status and approved indications are also unclear. As a result, there is limited information available on its safety profile and pharmacokinetic properties. Further research is needed to fully understand this compound. Its development history is also unclear.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | ETODROXIZINE |
|---|---|
| Drug class | etodroxizine |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Mechanism of action
Imagine your body's cells are like locks, and etodroxizine is a key that fits into one of those locks. When it binds to the lock, it can either turn it on or off, depending on the type of lock. However, the specific lock that etodroxizine binds to is currently unknown.
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Etodroxyzine CI brief — competitive landscape report
- Etodroxyzine updates RSS · CI watch RSS
Frequently asked questions about Etodroxyzine
What is Etodroxyzine?
How does Etodroxyzine work?
What is the generic name of Etodroxyzine?
What drug class is Etodroxyzine in?
What development phase is Etodroxyzine in?
Related
- Drug class: All etodroxizine drugs
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing